Cargando…
Longitudinal Plasma Measures of Trimethylamine N‐Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community‐Based Older Adults
BACKGROUND: Trimethylamine N‐oxide (TMAO) is a gut microbiota‐dependent metabolite of dietary choline, L‐carnitine, and phosphatidylcholine‐rich foods. On the basis of experimental studies and patients with prevalent disease, elevated plasma TMAO may increase risk of atherosclerotic cardiovascular d...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649305/ https://www.ncbi.nlm.nih.gov/pubmed/34398665 http://dx.doi.org/10.1161/JAHA.120.020646 |
_version_ | 1784610967543349248 |
---|---|
author | Lee, Yujin Nemet, Ina Wang, Zeneng Lai, Heidi T. M. de Oliveira Otto, Marcia C. Lemaitre, Rozenn N. Fretts, Amanda M. Sotoodehnia, Nona Budoff, Matthew DiDonato, Joseph A. McKnight, Barbara Tang, W. H. Wilson Psaty, Bruce M. Siscovick, David S. Hazen, Stanley L. Mozaffarian, Dariush |
author_facet | Lee, Yujin Nemet, Ina Wang, Zeneng Lai, Heidi T. M. de Oliveira Otto, Marcia C. Lemaitre, Rozenn N. Fretts, Amanda M. Sotoodehnia, Nona Budoff, Matthew DiDonato, Joseph A. McKnight, Barbara Tang, W. H. Wilson Psaty, Bruce M. Siscovick, David S. Hazen, Stanley L. Mozaffarian, Dariush |
author_sort | Lee, Yujin |
collection | PubMed |
description | BACKGROUND: Trimethylamine N‐oxide (TMAO) is a gut microbiota‐dependent metabolite of dietary choline, L‐carnitine, and phosphatidylcholine‐rich foods. On the basis of experimental studies and patients with prevalent disease, elevated plasma TMAO may increase risk of atherosclerotic cardiovascular disease (ASCVD). TMAO is also renally cleared and may interact with and causally contribute to renal dysfunction. Yet, how serial TMAO levels relate to incident and recurrent ASCVD in community‐based populations and the potential mediating or modifying role of renal function are not established. METHODS AND RESULTS: We investigated associations of serial measures of plasma TMAO, assessed at baseline and 7 years, with incident and recurrent ASCVD in a community‐based cohort of 4131 (incident) and 1449 (recurrent) older US adults. TMAO was measured using stable isotope dilution liquid chromatography–tandem mass spectrometry (laboratory coefficient of variation, <6%). Incident ASCVD (myocardial infarction, fatal coronary heart disease, stroke, sudden cardiac death, or other atherosclerotic death) was centrally adjudicated using medical records. Risk was assessed by multivariable Cox proportional hazards regression, including time‐varying demographics, lifestyle factors, medical history, laboratory measures, and dietary habits. Potential mediating effects and interaction by estimated glomerular filtration rate (eGFR) were assessed. During prospective follow‐up, 1766 incident and 897 recurrent ASCVD events occurred. After multivariable adjustment, higher levels of TMAO were associated with a higher risk of incident ASCVD, with extreme quintile hazard ratio (HR) compared with the lowest quintile=1.21 (95% CI, 1.02–1.42; P‐trend=0.029). This relationship appeared mediated or confounded by eGFR (eGFR‐adjusted HR, 1.07; 95% CI, 0.90–1.27), as well as modified by eGFR (P‐interaction <0.001). High levels of TMAO were associated with higher incidence of ASCVD in the presence of impaired renal function (eGFR <60 mL/min per 1.73 m(2): HR, 1.56 [95% CI, 1.13–2.14]; P‐trend=0.007), but not normal or mildly reduced renal function (eGFR ≥60 mL/min per 1.73 m(2): HR, 1.03 [95% CI, 0.85–1.25]; P‐trend=0.668). Among individuals with prior ASCVD, TMAO associated with higher risk of recurrent ASCVD (HR, 1.25 [95% CI, 1.01–1.56]; P‐trend=0.009), without significant modification by eGFR. CONCLUSIONS: In this large community‐based cohort of older US adults, serial measures of TMAO were associated with higher risk of incident ASCVD, with apparent modification by presence of impaired renal function and with higher risk of recurrent ASCVD. |
format | Online Article Text |
id | pubmed-8649305 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86493052022-01-14 Longitudinal Plasma Measures of Trimethylamine N‐Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community‐Based Older Adults Lee, Yujin Nemet, Ina Wang, Zeneng Lai, Heidi T. M. de Oliveira Otto, Marcia C. Lemaitre, Rozenn N. Fretts, Amanda M. Sotoodehnia, Nona Budoff, Matthew DiDonato, Joseph A. McKnight, Barbara Tang, W. H. Wilson Psaty, Bruce M. Siscovick, David S. Hazen, Stanley L. Mozaffarian, Dariush J Am Heart Assoc Original Research BACKGROUND: Trimethylamine N‐oxide (TMAO) is a gut microbiota‐dependent metabolite of dietary choline, L‐carnitine, and phosphatidylcholine‐rich foods. On the basis of experimental studies and patients with prevalent disease, elevated plasma TMAO may increase risk of atherosclerotic cardiovascular disease (ASCVD). TMAO is also renally cleared and may interact with and causally contribute to renal dysfunction. Yet, how serial TMAO levels relate to incident and recurrent ASCVD in community‐based populations and the potential mediating or modifying role of renal function are not established. METHODS AND RESULTS: We investigated associations of serial measures of plasma TMAO, assessed at baseline and 7 years, with incident and recurrent ASCVD in a community‐based cohort of 4131 (incident) and 1449 (recurrent) older US adults. TMAO was measured using stable isotope dilution liquid chromatography–tandem mass spectrometry (laboratory coefficient of variation, <6%). Incident ASCVD (myocardial infarction, fatal coronary heart disease, stroke, sudden cardiac death, or other atherosclerotic death) was centrally adjudicated using medical records. Risk was assessed by multivariable Cox proportional hazards regression, including time‐varying demographics, lifestyle factors, medical history, laboratory measures, and dietary habits. Potential mediating effects and interaction by estimated glomerular filtration rate (eGFR) were assessed. During prospective follow‐up, 1766 incident and 897 recurrent ASCVD events occurred. After multivariable adjustment, higher levels of TMAO were associated with a higher risk of incident ASCVD, with extreme quintile hazard ratio (HR) compared with the lowest quintile=1.21 (95% CI, 1.02–1.42; P‐trend=0.029). This relationship appeared mediated or confounded by eGFR (eGFR‐adjusted HR, 1.07; 95% CI, 0.90–1.27), as well as modified by eGFR (P‐interaction <0.001). High levels of TMAO were associated with higher incidence of ASCVD in the presence of impaired renal function (eGFR <60 mL/min per 1.73 m(2): HR, 1.56 [95% CI, 1.13–2.14]; P‐trend=0.007), but not normal or mildly reduced renal function (eGFR ≥60 mL/min per 1.73 m(2): HR, 1.03 [95% CI, 0.85–1.25]; P‐trend=0.668). Among individuals with prior ASCVD, TMAO associated with higher risk of recurrent ASCVD (HR, 1.25 [95% CI, 1.01–1.56]; P‐trend=0.009), without significant modification by eGFR. CONCLUSIONS: In this large community‐based cohort of older US adults, serial measures of TMAO were associated with higher risk of incident ASCVD, with apparent modification by presence of impaired renal function and with higher risk of recurrent ASCVD. John Wiley and Sons Inc. 2021-08-16 /pmc/articles/PMC8649305/ /pubmed/34398665 http://dx.doi.org/10.1161/JAHA.120.020646 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Lee, Yujin Nemet, Ina Wang, Zeneng Lai, Heidi T. M. de Oliveira Otto, Marcia C. Lemaitre, Rozenn N. Fretts, Amanda M. Sotoodehnia, Nona Budoff, Matthew DiDonato, Joseph A. McKnight, Barbara Tang, W. H. Wilson Psaty, Bruce M. Siscovick, David S. Hazen, Stanley L. Mozaffarian, Dariush Longitudinal Plasma Measures of Trimethylamine N‐Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community‐Based Older Adults |
title | Longitudinal Plasma Measures of Trimethylamine N‐Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community‐Based Older Adults |
title_full | Longitudinal Plasma Measures of Trimethylamine N‐Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community‐Based Older Adults |
title_fullStr | Longitudinal Plasma Measures of Trimethylamine N‐Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community‐Based Older Adults |
title_full_unstemmed | Longitudinal Plasma Measures of Trimethylamine N‐Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community‐Based Older Adults |
title_short | Longitudinal Plasma Measures of Trimethylamine N‐Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community‐Based Older Adults |
title_sort | longitudinal plasma measures of trimethylamine n‐oxide and risk of atherosclerotic cardiovascular disease events in community‐based older adults |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649305/ https://www.ncbi.nlm.nih.gov/pubmed/34398665 http://dx.doi.org/10.1161/JAHA.120.020646 |
work_keys_str_mv | AT leeyujin longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults AT nemetina longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults AT wangzeneng longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults AT laiheiditm longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults AT deoliveiraottomarciac longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults AT lemaitrerozennn longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults AT frettsamandam longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults AT sotoodehnianona longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults AT budoffmatthew longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults AT didonatojosepha longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults AT mcknightbarbara longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults AT tangwhwilson longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults AT psatybrucem longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults AT siscovickdavids longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults AT hazenstanleyl longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults AT mozaffariandariush longitudinalplasmameasuresoftrimethylaminenoxideandriskofatheroscleroticcardiovasculardiseaseeventsincommunitybasedolderadults |